Sarepta sells FDA priority voucher for $125 million

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) says it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to US biotech major Gilead Sciences (Nasdaq: GILD) for $125 million.

Investors were not overly impressed, with Sarepta’s shares up just 1.4% at $28.68 by close of trading yesterday following the announcement.

Sarepta received the PRV when Exondys 51 (eteplirsen)was approved by the US Food and Drug Administration for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping, making it the first drug to gain FDA approval for this rare disease.